4[5]Iwai H. Pjasma exchange remoral of endotoxin and cytokines in acate heptc failure Crit Cave Med, 1998, 26 (5): 873
5[7]Goidstein AL. Badamchian M, Paino J, et al. Thymosinal Current Status of human trials and potential applications in clinical therapy, in Maurer HR, Goldstrin AL, Hagar ED, eds, Thymic peptides in preclinical and clinical medicine, 1 st ed. New York: Zuckschwerdt,1997, 131
6[10]Yoshiba M, Ionoek, Sekiyanak, et al. Favovable effect of new artificial liver Supporton Survival of patients with fulminant hepatic failure Artiforgans, 1996, 12: 534
7[17]Takahashi Y. Evaluation of the special therapies in fulminant viral hepatits-a multi-in stitution study. Nippon shokakibyo Gakkai Zasshi, 1995, 92:7
8[18]Toborek M, Kopieczna GE, Drozdz M, er al. Increased Iipid perroxidation and antioxidant activity in methionine induced hepatitis in rabbits. Natririon, 1996, 12:534
